替吉奥联合康莱特注射液姑息治疗晚期胰腺癌临床观察  

Clinical Observation on Tegafur Gimeracil Oteracil Potassium Capsules Combined With Kanglaite Injection in Palliative Treatment of Advanced Pancreatic Carcinoma

作　　者：邹文兵[1] 董扬扬[1] 柳燕[1] 庄奕煌[1] 

机构地区：[1]福建省泉州市第一医院肿瘤外科,福建泉州362000

出　　处：《中国卫生标准管理》2016年第13期136-138,共3页China Health Standard Management

摘　　要：目的研究替吉奥联合康莱特注射液姑息治疗晚期胰腺癌的临床疗效。方法选取在我院治疗的晚期胰腺癌患者60例,将其随机分为两组,对照组患者口服替吉奥胶囊治疗,观察组给予替吉奥联合康莱特注射液治疗,对比分析两组临床疗效。结果对照组患者治疗有效率为36.7%、疾病控制率为66.7%,观察组分别为50.0%、86.7%,两组对比差异无统计学意义(P>0.05);对照组患者疼痛改善率为50.0%、体质量改善率36.7%、KPS评分改善率为43.3%,低于观察组的76.7%、63.3%、70.0%,差异有统计学意义(P<0.05)。结论替吉奥联合康莱特注射液姑息治疗晚期胰腺癌患者临床效果较好,可减轻患者的痛苦,药物毒性反应少,提高了患者的生活质量。Objective To study the clinical curative efficacy of tegafur gimeracil oteracil potassium capsules combined with Kanglaite injection in paliative treatment of advanced pancreatic carcinoma.Methods 60 cases of patients with advanced pancreatic carcinoma in our hospital were randomly divided into two groups. The control group received only tegafur gimeracil oteracil potassium capsules and the observation group received tegafur gimeracil oteracil potassium capsules combined with Kanglaite injection. The clinical curative efficacy of two groups were compared and analyzed. ResultsThe curative effect and disease control rate of the control group were 36.7% and 66.7%,respectively; the observation group were 50.0%and 86.7% respectively,the difference of the two groups had no statistical significance（P〉0.05）. The pain relief rate,improved weight rate, improved of Karnofsky performance status （KPS） scale rate of control group （50.0%,36.7 %,43.3%） was lower than observation group （76.7%, 63.3%,70.0%）,and there was significant difference（P〈0.05）.Conclusion Tegafur gimeracil oteracil potassium capsules combined with Kanglaite injection in paliative treatment of advanced pancreatic carcinomathe has good clinical curative efficacy and can relieve patients’ pain,it has little drug toxicity reaction and improves the quality of life.

关 键 词：替吉奥 康莱特注射液 晚期胰腺癌 

分 类 号：R735.9[医药卫生—肿瘤]